LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Innoviva Inc

Closed

SectorHealthcare

19.33 -0.92

Overview

Share price change

24h

Current

Min

19.24

Max

19.59

Key metrics

By Trading Economics

Income

110M

64M

Sales

12M

100M

P/E

Sector Avg

35.895

35.664

Profit margin

63.508

Employees

127

EBITDA

111M

84M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+107.8% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

124M

1.3B

Previous open

20.25

Previous close

19.33

News Sentiment

By Acuity

12%

88%

11 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Sept 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 Sept 2025, 16:43 UTC

Major Market Movers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 Sept 2025, 16:42 UTC

Major Market Movers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 Sept 2025, 16:35 UTC

Major Market Movers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 Sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 Sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 Sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 Sept 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 Sept 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 Sept 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 Sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 Sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 Sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 Sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 Sept 2025, 17:50 UTC

Acquisitions, Mergers, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 Sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 Sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 Sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

107.8% upside

12 Months Forecast

Average 40.25 USD  107.8%

High 55 USD

Low 26 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

11 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat